Drug Landscape ›
Gebauer's Ethyl Chloride ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 8
Most-reported reactions
Application Site Discolouration — 1 report (12.5%) Application Site Induration — 1 report (12.5%) Blister — 1 report (12.5%) Chemical Injury — 1 report (12.5%) Implant Site Erythema — 1 report (12.5%) Implant Site Pain — 1 report (12.5%) Post Procedural Complication — 1 report (12.5%) Therapeutic Response Decreased — 1 report (12.5%)
Source database →
Gebauer's Ethyl Chloride in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Gebauer's Ethyl Chloride approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Gebauer's Ethyl Chloride in United States?
Henry Ford Health System is the originator. The local marketing authorisation holder may differ — check the official source linked above.